BDBM575602 (3R,3'R)-1,1'-(((((2,2'-dimethyl-[1,1'- biphenyl]-3,3'-diyl)bis(azanediyl))bis (carbonyl))bis(4-cyclopropylpyridine- 6,3-diyl))bis(methylene))bis(pyrrolidine- 3-carboxylic acid)::US11459339, Example 132

SMILES Cc1c(NC(=O)c2cc(C3CC3)c(CN3CC[C@H](C3)C(O)=O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN3CC[C@H](C3)C(O)=O)cn2)c1C

InChI Key InChIKey=LGJDDJWAFGOGBY-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 575602   

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575602(US11459339, Example 132 | (3R,3'R)-1,1'-(((((2,2'-...)
Affinity DataIC50: 0.200nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent